Dyck, Garrison J. B.; Raj, Pema; Zieroth, Shelley; Dyck, Jason R. B.; Ezekowitz, Justin A. published the artcile< The effects of resveratrol in patients with cardiovascular disease and heart failure: a narrative review>, Application In Synthesis of 501-36-0 , the main research area is review resveratrol cardioprotectant cardiovascular disease heart failure; CVD; heart failure; resveratrol.
A review. Cardiovascular disease (CVD) is the main cause of death globally and responsible for the second highest number of deaths in Canada. Medical advancements in the treatment of CVD have led to patients living longer with CVD but often progressing to another condition called heart failure (HF). As a result, HF has emerged in the last decade as a major medical concern. Fortunately, various “”traditional”” pharmacotherapies for HF exist and have shown success in reducing HF-associated mortality. However, to augment the treatment of patients with CVD and/or HF, alternative pharmacotherapies using nutraceuticals have also shown promise in the prevention and treatment of these two conditions. One of these natural compounds considered to potentially help treat HF and CVD and prevent their development is resveratrol. Herein, we review the clin. findings of resveratrol’s ability to be used as an effective treatment to potentially help treat HF and CVD. This will allow us to gain a more fulsome appreciation for the effects of resveratrol in the health outcomes of specific patient populations who have various disorders that constitute CVD.
International Journal of Molecular Sciences published new progress about Cardioprotective agents. 501-36-0 belongs to class alcohols-buliding-blocks, and the molecular formula is C14H12O3, Application In Synthesis of 501-36-0 .
Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts